Oppenheimer & CO Inc Tcr2 Therapeutics Inc. Transaction History

Oppenheimer & CO Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 07, 2023	SELL	$0.83 - $1.44 $830 - $1,440	-1,000 Reduced 2.57%	37,950 $37,000
Q3 2022 Nov 14, 2022	BUY	$1.86 - $3.75 $2,418 - $4,875	1,300 Added 3.45%	38,950 $70,000
Q1 2022 May 12, 2022	SELL	$2.4 - $4.71 $18,480 - $36,267	-7,700 Reduced 16.98%	37,650 $104,000
Q4 2021 Feb 02, 2022	SELL	$4.58 - $8.34 $15,343 - $27,939	-3,350 Reduced 6.88%	45,350 $211,000
Q3 2021 Nov 12, 2021	BUY	$8.44 - $18.35 $411,028 - $893,645	48,700 New	48,700 $414,000

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Oppenheimer & CO Inc, based on Form 13F filings with the SEC.

Stay updated on Oppenheimer & CO Inc with notifications on news.